MapLight Therapeutics/$MPLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MapLight Therapeutics
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Ticker
$MPLT
Sector
Primary listing
Employees
133
Headquarters
Website
MPLT Metrics
BasicAdvanced
$1.3bn
-
-$10.07
-
-
Price and volume
Market cap
$1.3bn
52-week high
$33.28
52-week low
$12.24
Average daily volume
280k
Financial strength
Current ratio
22.91
Quick ratio
21.712
Long term debt to equity
1.168
Total debt to equity
1.398
Profitability
EBITDA (TTM)
-209.469
Management effectiveness
Return on assets (TTM)
-49.51%
Return on equity (TTM)
-80.95%
Valuation
Price to book
3.16
Price to tangible book (TTM)
3.16
Price to free cash flow (TTM)
-3.372
Free cash flow yield (TTM)
-29.66%
Free cash flow per share (TTM)
-8.292
Growth
Earnings per share change (TTM)
-90.56%
What the Analysts think about MPLT
Analyst ratings (Buy, Hold, Sell) for MapLight Therapeutics stock.
MPLT Financial Performance
Revenues and expenses
MPLT Earnings Performance
Company profitability
MPLT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs